PLUS1
18.55
-0.63 (-3.28%)
-0.63 (-3.28%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cara Therapeutics Inc | CARA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.63 | -3.28% | 18.55 | 18:01:17 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 18.505 | 18.36 | 19.26 | 18.55 | 19.18 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 18.35 | 20.00 | 1.65 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,186 | 454,006 | $ 18.88 | $ 8,570,023 | 475,098 | 8.88 - 21.64 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:30:33 | 19 | $ 18.3184 | USD |
Cara Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 924.39M | 49.83M | 43.98M | $ 19.89M | $ - | -2.49 | -9.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Cara Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/25/2021 | 17:32 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/11/2021 | 07:00 | GlobeNewswire Inc. | Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the.. |
| 1/06/2021 | 07:00 | GlobeNewswire Inc. | Cara Therapeutics to Present at the 39th Annual J.P. Morgan.. |
| 12/30/2020 | 18:17 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 12/30/2020 | 18:16 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 12/30/2020 | 18:15 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 12/30/2020 | 18:12 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CARA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 20.24 | 21.64 | 18.18 | 19.54 | 558,533 | -1.69 | -8.35% |
| 1 Month | 15.30 | 21.64 | 14.8701 | 17.89 | 502,309 | 3.25 | 21.24% |
| 3 Months | 13.26 | 21.64 | 13.20 | 16.13 | 448,498 | 5.29 | 39.89% |
| 6 Months | 17.26 | 21.64 | 12.30 | 15.44 | 409,004 | 1.29 | 7.47% |
| 1 Year | 15.60 | 21.64 | 8.88 | 15.32 | 457,091 | 2.95 | 18.91% |
| 3 Years | 15.17 | 27.55 | 8.88 | 17.49 | 672,000 | 3.38 | 22.28% |
| 5 Years | 10.80 | 28.50 | 4.26 | 15.05 | 932,163 | 7.75 | 71.76% |
Cara Therapeutics Description
| Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. |
